Ben-Shoshan, M. Et Al. 2022. Ligelizumab for adolescent patients with CSU: first results from a dedicated Phase 2b study. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY , vol.149, no.2 .

Ben-Shoshan, M., ŞEKEREL, B. E., Staubach-Renz, P., Alvaro-Lozano, M., Maurer, M., Drollmann, A., ... Bienczak, A.(2022). Ligelizumab for adolescent patients with CSU: first results from a dedicated Phase 2b study. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY , vol.149, no.2.

Ben-Shoshan, Moshe Et Al. "Ligelizumab for adolescent patients with CSU: first results from a dedicated Phase 2b study," JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY , vol.149, no.2, 2022

Ben-Shoshan, Moshe Et Al. "Ligelizumab for adolescent patients with CSU: first results from a dedicated Phase 2b study." JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY , vol.149, no.2, 2022

Ben-Shoshan, M. Et Al. (2022) . "Ligelizumab for adolescent patients with CSU: first results from a dedicated Phase 2b study." JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY , vol.149, no.2.

@article{article, author={Moshe Ben-Shoshan Et Al. }, title={Ligelizumab for adolescent patients with CSU: first results from a dedicated Phase 2b study}, journal={JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY}, year=2022}